Overview
BPC-157 and TB-500 are among the most extensively researched repair-associated peptides in preclinical science. Both have demonstrated tissue repair properties in animal studies, but they operate through entirely different biological mechanisms, act on different cell types, and address different aspects of the repair cascade. Understanding these differences is essential for designing research protocols.
BPC-157: Gastric Pentadecapeptide and Angiogenic Signaling
BPC-157 (Body Protection Compound 157) is a 15-amino acid sequence derived from human gastric juice protein BPC. Its primary mechanism involves upregulation of the VEGFR2/eNOS/NO signaling axis, promoting angiogenesis and vascular remodeling at injury sites. BPC-157 also modulates the nitric oxide system, stimulates expression of growth factor receptors (EGF-R, FGFR), and demonstrates cytoprotective effects on gastrointestinal mucosa in murine models. It is active both systemically and locally.
TB-500: Thymosin Beta-4 Fragment and Actin Dynamics
TB-500 corresponds to the actin-binding domain of Thymosin Beta-4 (Tβ4), specifically the LKKTETQ sequence region. Its primary mechanism is sequestering G-actin (monomeric), which promotes cell migration, reduces inflammation, and enables faster tissue remodeling. TB-500 upregulates metalloproteinases and stimulates keratinocyte and endothelial cell migration — making it particularly relevant to wound closure, cardiac repair, and neural regeneration research.
Key Differences
| Parameter | BPC-157 | TB-500 |
|---|---|---|
| Origin | Human gastric BPC protein | Thymosin Beta-4 LKKTETQ fragment |
| Length | 15 amino acids | 43 amino acids (full Tβ4 fragment) |
| MW | 1,419.55 Da | 4,963.44 Da |
| Primary mechanism | VEGFR2/eNOS/NO signaling | G-actin sequestering, cell migration |
| Key effect | Angiogenesis, GI protection | Tissue remodeling, migration |
| GI research | Extensively studied | Limited |
| Cardiac/neural models | Limited | Extensively studied |
Research Applications
BPC-157 is the primary choice for gastrointestinal injury models, inflammatory bowel research, and studies of tendon-to-bone healing. TB-500 is preferred for cardiac infarct models, dermal wound models requiring cell migration endpoints, and neural repair studies. The two are frequently co-administered in preclinical injury models due to their mechanistic complementarity — BPC-157 driving vascular supply while TB-500 enables cellular migration and matrix remodeling.
Laboratory Considerations
BPC-157 is available in 5mg and 10mg vials; TB-500 in 5mg vials. Both are lyophilized and reconstituted with bacteriostatic water. TB-500’s higher molecular weight (4,963 Da) requires slightly longer dissolution time — gentle swirling for 2–3 minutes is recommended. BPC-157 solutions are stable at 4°C for 3 weeks; TB-500 for up to 4 weeks. Both peptides should be stored at −20°C long-term and protected from light.
Research Disclaimer: All compounds discussed are intended exclusively for laboratory and research purposes. This content is not medical advice. Bastion Peptides products are not approved for human use, consumption, or therapeutic application.
